References
- Paul SM , MytelkaDS, DunwiddieCTet al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov.9, 203–214 (2010).
- Arrowsmith J , MillerP. Trial watch: phase II and phase III attrition rates 2011–2012. Nat. Rev. Drug Discov.12, 569 (2013).
- Smith AJ . New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics. J. Biomol. Screen. doi:10.1177/1087057114562544 (2014) ( Epub ahead of print).
- Hampel H , SchneiderLS, GiacobiniEet al. Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev. Neurother.15, 83–105 (2015).
- Tayeb HO , MurrayED, PriceBH, TaraziFI. Bapineuzumab and solanezumab for Alzheimer’s disease: is the ‘amyloid cascade hypothesis’ still alive?Expert Opin. Biol. Ther.13, 1075–1084 (2013).
- Levites Y , SmithsonLA, PriceRWet al. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer’s isease mouse models. FASEB J.20, 2576–2578 (2006).
- Pardridge WM , BuciakJL, FridenPM. Selective transport of an anti-transferrin receptor antibody through the blood–brain barrier in vivo. J. Pharmacol. Exp. Ther.259, 66–70 (1991).
- Jones AR , ShustaEV. Blood–brain barrier transport of therapeutics via receptor-mediation. Pharm. Res.24, 1759–1771 (2007).
- Boado RJ , LuJZ, HuiEK, PardridgeWM. Insulin receptor antibody–sulfamidase fusion protein penetrates the primate blood–brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells. Mol. Pharm.11, 2928–2934 (2014).
- Yu YJ , ZhangY, KenrickMet al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med.3(84), 84ra44 (2011).
- Couch JA , YuYJ, ZhangYet al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood–brain barrier. Sci. Transl. Med.5, 183ra57, 1–12 (2013).
- Yu YJ , AtwalJK, ZhangYet al. Therapeutic bispecific antibodies cross the blood–brain barrier in nonhuman primates. Sci. Transl. Med.6, 261ra154 (2014).
- Niewoehner J , BohrmannB, CollinLet al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron81, 49–60 (2014).
- ABBVIE, INC. : WO 2014089209 A2, AbbVie Deutschland GmbH & Co. KG (2014).
- Hasler J , McGowanE, RutkowskiL. Species cross-reactive single domain antibodies (VNARs) to the transferrin receptor 1 (TFR1) that cross the BBB. Presented at: Cold Spring Harbor Blood–Brain Barrier Conference. Cold Spring Harbor, NY, USA, 10–13 December 2014 ( Abstract book 32).
- Tanha J , MuruganandamA, StanimirovicD. Phage display technology for identifying specific antigens on brain endothelial cells. Methods Mol. Med.89, 435–449 (2003).
- Muruganandam A , TanhaJ, NarangS, StanimirovicD. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood–brain barrier endothelium. FASEB J.16, 240–242 (2002).
- Stanimirovic DB , KemmerichK, HaqqaniAS, FarringtonGK. Engineering and pharmacology of blood–brain barrier-permeable bispecific antibodies. Adv. Pharmacol.71, 301–335 (2014).
- Farrington GK , Caram-SalasN, HaqqaniASet al. A novel platform for engineering blood–brain barrier-crossing bispecific biologics. FASEB J.28, 4764–4778 (2014).
- Iliff JJ , WangM, ZeppenfeldDMet al. Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain. J. Neurosci.33, 18190–18199 (2013).